NCT06634979 Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
| NCT ID | NCT06634979 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fudan University |
| Condition | Lung Cancer (NSCLC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 684 participants |
| Start Date | 2024-05-01 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 684 participants in total. It began in 2024-05-01 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study investigated the efficacy and safety of a selective lymph node strategy (no lower mediastinal lymph node dissection for upper lobe tumors and no upper mediastinal lymph node dissection for lower lobe tumors) in patients with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter cT1N0M0 infiltrating NSCLC, aiming to more accurately assess the prognosis of the selective lymph node dissection strategy for nodes with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter.
Eligibility Criteria
Inclusion Criteria: * Volunteer to participate in a clinical study and be willing to follow and have the ability to complete all trial procedures; * Age 18-80 years at time of signing informed consent (including threshold); * ECOG score 0 or 1; * No previous surgery for lung cancer; * Intraoperative or postoperative pathologically confirmed non-small cell lung cancer; * Single pulmonary nodule with mixed ground glass on CT, or multiple pulmonary nodules but the main lesion is the above nodules; * The proportion of solid components of the nodule is between 0.5 and 1, and the total size of the nodule is less than or equal to 2 cm; * Patients with clinical stage T1N0M0 surgically resectable; * Primary treatment without radiotherapy or chemotherapy. Exclusion Criteria: * T1N0M0 with a clinical stage other than 0.5 \< CTR \< 1 and a diameter of ≤ 2 cm; * Inability to perform complete surgical resection; * cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer; * Previous surgery for lung cancer; * Patients who have received radiotherapy or chemotherapy for non-primary treatment.
Contact & Investigator
Haiquan Chen
PRINCIPAL INVESTIGATOR
Fudan University
Frequently Asked Questions
Who can join the NCT06634979 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Lung Cancer (NSCLC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06634979 currently recruiting?
Yes, NCT06634979 is actively recruiting participants. Contact the research team at 18301050196@fudan.edu.cn for enrollment information.
Where is the NCT06634979 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06634979 clinical trial?
NCT06634979 is sponsored by Fudan University. The principal investigator is Haiquan Chen at Fudan University. The trial plans to enroll 684 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.